R&D Capabilities

Endo has active research and development programs in men’s health, orthopedics, endocrinology and medical aesthetics. Beyond these therapeutic areas, we also have focused development in the area of sterile injectables, and complex Gx products. Our Core Team Development Model brings together experts in R&D strategy, clinical development, regulatory affairs, R&D operations, pharmacovigilance and risk management to develop medicines that can safely and effectively be delivered to patients.

Within our specialty research and development arm, we are focused on applying the latest technology to identify new targets to address unmet medical needs. In recent years, our extensive research has confirmed the role of collagenase in the treatment of several connective tissue disorders and medical aesthetic conditions that involve fibrous collagen depositions and/or thickened collagen fibers. Successful regulatory approvals of different presentations of collagenase across multiple therapeutic areas have bolstered our team’s dedication and commitment to deliver therapeutic solutions that can address areas of continued unmet patient need. For this reason, this continues to be a key research focus for Endo.

Endo also has a long history of developing and delivering generic pharmaceutical products in a variety of therapeutic categories including antihypertensives, analgesics, antibiotics, antidepressants and antipsychotics. Bringing a bio-equivalent medicine to market in the form of a generic product requires specialized bioequivalence product design expertise, consistent manufacturing processes and demonstrated bioequivalence studies to prove the medicine’s effectiveness in relation to the original reference product. At all times, high standards for quality, efficacy and safety must be maintained. Our team is practiced and has demonstrated our ability to meet these standards.